Next Article in Journal
Development of Effective Anticancer Drug Candidates against Breast and Colon Cancers
Previous Article in Journal
The Effect of Pycnogenol and Paclitaxel on DNA Damage in Human Breast Cancer Cell Line
Article Menu

Article Versions

Export Article

Open AccessAbstract
Proceedings 2017, 1(10), 973; doi:10.3390/proceedings1100973

Pristimerin is a Promising Natural Product against Breast Cancer in vitro and in vivo through Apoptosis and the Blockage of Autophagic Flux

1
Department of Biology, Faculty of Arts and Sciences, Uludag University, Bursa 16059, Turkey
2
Department of Pharmacology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece
3
Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza University of Roma, piazzale Aldo Moro 5, 00185 Roma, Italy
4
Department of Clinical Biochemistry, Faculty of Medicine, Istinye University, Istanbul 34010, Turkey
Presented at the 2nd International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 8–11 November, 2017.
*
Author to whom correspondence should be addressed.
Published: 15 November 2017
Download PDF [138 KB, uploaded 29 November 2017]

Abstract

The exploration of natural products is of importance because the management of cancer is still not satisfactory. Pristimerin is a naturally occurring triterpenoid that has been shown to suppress the proliferation of various cancer cell lines at relatively lower concentrations, of which the IC50 values are around 0.5–4 μM. Its cytotoxic potential on particularly cancer stem cells (CSCs) should be much more important due to the CSCs’ recent role in recurrence of cancer. Although pristimerin exerted growth inhibitory activity in various cancer cells, the mechanisms is still debatable. Its antigrowth effect seems to involve the blockage of autophagic process as well. In our studies, pristimerin showed an anti-growth effect on cancer cells and cancer stem cells with IC50 values ranging at 0.38–1.75 µM. Apoptosis was induced in MCF-7 and MCF-7s (CSCs) cells. It also resulted in an incompleted autophagy as evidenced by the increase of autophagy-related proteins (P62 and LC3-II) as well as an unfolded protein response (UPR). Moreover, it inhibited the growth of xenografts in NOD/SCID mice. Taken together, pristimerin deserves further attention in terms of its use for the treatment of breast cancer. In this talk, quite an unusal cytotoxic potential of pristimerin will be discussed.
Keywords: pristimerin; autophagic flux; NOD/SCID mice pristimerin; autophagic flux; NOD/SCID mice
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Cevatemre, B.; Dimas, K.; Botta, B.; Ulukaya, E. Pristimerin is a Promising Natural Product against Breast Cancer in vitro and in vivo through Apoptosis and the Blockage of Autophagic Flux. Proceedings 2017, 1, 973.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Proceedings EISSN 2504-3900 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top